Celek Pharmaceuticals today announced that the National Cancer Institute (NCI) has awarded the Company a Phase I Small Business Innovation Research (SBIR) Contract to support development of CEL-031, Celek’s targeted, first-in-class oncology drug candidate for the treatment of bladder cancer.